Adherence and persistence to second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia

被引：0
|
作者：
Trivedi, Digisha
Amin, Shahla
Zhu, Ling
Joo, Sam
Kawabata, Hugh
Darkow, Theodore
Hebden, Tony
机构：
[1] Bristol Myers Squibb Co, Hlth Serv, Plainsboro, NJ USA
[2] Bristol Myers Squibb Co, Global Hlth Econ & Outcomes Res, Pennington, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17009
引用
收藏
页数：1
相关论文
共 50 条
  • [41] VALIDATION OF A PROGNOSTIC SCORING SYSTEM IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER IMATINIB FAILURE
    Boquimpani, C.
    Schaffel, R.
    Graca, D.
    Mesquita, C.
    Peixoto, D.
    Madeira, T.
    Wendling, P.
    Eller, F.
    Biasoli, I.
    Spector, N.
    HAEMATOLOGICA, 2013, 98 : 553 - 553
  • [42] Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
    Jabbour, Elias
    Kantarjian, Hagop M.
    O'Brien, Susan
    Shan, Jianqin
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Rios, Mary Beth
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4260 - 4265
  • [43] Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront
    Breccia, Massimo
    Molica, Matteo
    Colafigli, Gioia
    Zacheo, Irene
    Latagliata, Roberto
    Tafuri, Agostino
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2206 - 2207
  • [44] Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia Treated with First- Versus Second-Generation Tyrosine Kinase Inhibitors
    Shacham Abulafia, Adi
    Shemesh, Sivan
    Rosenmann, Lena
    Berger, Tamar
    Leader, Avi
    Sharf, Giora
    Raanani, Pia
    Rozovski, Uri
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 9
  • [45] CLINICAL SIGNIFICANCE OF EARLY MOLECULAR RESPONSES IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH FIRST-LINE SECOND-GENERATION TYROSINE KINASE INHIBITORS
    Lee, S.
    Choi, S.
    Kim, S.
    Bang, J.
    Oh, Y.
    Park, J.
    Jeon, H.
    Jang, E.
    Kim, D.
    HAEMATOLOGICA, 2013, 98 : 51 - 52
  • [46] Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors
    Al-Jadir, Riyam
    Alalsaidissa, Jaffar
    IRAQI JOURNAL OF HEMATOLOGY, 2020, 9 (02) : 131 - 137
  • [47] Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors
    Marce, Silvia
    Zamora, Lurdes
    Cabezon, Marta
    Xicoy, Blanca
    Boque, Concha
    Fernandez, Cristalina
    Grau, Javier
    Navarro, Jose-Tomas
    Fernandez de Sevilla, Alberto
    Ribera, Josep-Maria
    Feliu, Evarist
    Milla, Fuensanta
    MEDICINA CLINICA, 2013, 141 (03): : 95 - 99
  • [48] Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
    Kekale, Meri
    Talvensaari, Kimmo
    Koskenvesa, Perttu
    Porkka, Kimmo
    Airaksinen, Marja
    PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 1619 - 1627
  • [49] Impact of Prior Second-Generation Tyrosine Kinase Inhibitors on the Outcome of Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia.
    Benedicte, Deau
    Emmanuel, Bachy
    Nicole, Raus
    Franck-emmanuel, Nicolini
    Delphine, Rea
    Oumedaly, Reman
    Natacha, Maillard
    Ame, Shanti
    Nathalie, Fegueux
    Valerie, Coiteux
    Martine, Gardembas
    Aude, Charbonnier
    Anne, Huyn
    Yves, Cahn Jean
    Agnes, Buzyn
    BLOOD, 2010, 116 (21) : 933 - 933
  • [50] Second-generation tyrosine kinase inhibitors for patients resistant to imatinib
    Rousselot, Philippe
    HEMATOLOGIE, 2006, 12 (04): : 227 - 228
12345